Pregnancy outcome was documented, including mode of delivery, gestational age at delivery, birthweight, and general health of the newborn. Simple statistics were carried out using the features of Microsoft Excel software. A total of 52,430 medical records were screened for compatibility. Two hundred sixty-eight women were eligible to participate based on their pretravel questionnaire,

and were contacted. Forty-nine (18.3%) of these women were actually pregnant during travel and 46 consented to participate. Thus, the incidence of travel in pregnancy was 0.93/1000 travelers, or 1.86/1000 female travelers. Thirty-three women (71.7%) were pregnant before departure, 22 (67%) Sirolimus mouse of whom were in the first trimester (gestational age 4–15 w), 10 in the second trimester (gestational age 16–28 w) (30%), and 1 (3%) in the third

trimester. Thirteen women became pregnant during travel. Demographic and obstetrical data are presented Dabrafenib in Table 1. Thirty-three women traveled to East Asia (Thailand, India, Vietnam, Myanmar, Laos, Sri Lanka, and China), 8 to South and Central America (Mexico, Argentina, Guatemala, Cuba, Peru, Bolivia, and Chile), and 5 to Africa (Nigeria, Kenya, Ethiopia, Zanzibar, South Africa). The most popular destination was Thailand (23 women). Forty women traveled for leisure, four for business, and two for visiting family. No complications or unusual events,

including deep vein thrombophlebitis, were reported during Etofibrate or following air travel. Health issues during travel are presented in Table 2. Vaccinations administered before travel included hepatitis A and typhoid—combined, hepatitis A, hepatitis B, meningococcal, polio, diphtheria-tetanus, typhoid, yellow fever, rabies, and Japanese encephalitis. Four women received four vaccines, 1 received three vaccines, 10 received two vaccines, 17 received a single vaccine, and 14 received no vaccines. A total of 56 vaccines were given overall. The most commonly administered vaccine was against typhoid fever. All 13 women who were not yet pregnant at departure were vaccinated, with a total of 26 vaccinations. Nineteen of the 33 (58%) women who were pregnant at departure received vaccinations, with a total of 30 vaccines (0.9 per woman). Only one yellow fever vaccine was administered to a subject who was not yet pregnant at departure. In total, three women required medical therapy at a clinic during travel, one of whom underwent a minor surgical procedure for removal of helminthic skin infection, another received intravenous fluids, and a third was given paracetamol.